Dosing & Uses
AdultPediatric
Chronic Kidney Disease
Pending FDA approval for patients aged ≥12 years with chronic kidney disease caused by Alport syndrome
Chronic Kidney Disease
Pending FDA approval for patients aged ≥12 years with chronic kidney disease caused by Alport syndrome
Next:
Pharmacology
Mechanism of Action
Activates nuclear factor erythroid 2-related factor 2 (Nrf2), a transcription factor that induces molecular pathways that promote resolution of inflammation by restoring mitochondrial function, reducing oxidative stress, and inhibiting proinflammatory signaling
Previous
Next:
Images
No images available for this drug.
Previous
Next:
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.
